A STUDY TO UNDERSTAND THE DEVELOPMENT OF COCAINE HYDROLASE FOR THERAPEUTICAL TREATMENT OF COCAINE ABUSE TREATMENT

Shi Yanhua[1], Farra Aidah Jumuddin[1]

[1]Lincoln University College, Petaling Jaya, Malaysia.

ABSTRACT

There are currently few pharmaceutical options for the treatment of cocaine addiction, which is a major problem in public health. The goal of this research was to create an engineered enzyme called cocaine hydrolase (CocH) that could quickly break down cocaine into inactive metabolites, lessening the drug's impact on the body and mind. In order to maximize its catalytic effectiveness, stability, and selectivity while minimizing off-target effects, the structural optimization of CocH is being investigated in this study. Research in this area focuses on enzyme engineering by means of protein design, characterizing CocH variations in vitro and in vivo, and conducting preclinical evaluations of their therapeutic potential. The results show that improved CocH reduces drug-induced behavioral reactions in animal models and efficiently speeds cocaine metabolism. In order to guarantee that CocH is viable for clinical use, the research also explores possible immunogenicity, safety, and delivery methods. The potential of enzyme-based treatments as an innovative method of treating cocaine addiction is shown by this study, which opens up new avenues for their usage in addiction medicine. Addiction to cocaine is a rising public health concern that has far-reaching effects on people's mental health, relationships, and finances. There has been a lot of study on cocaine dependency, but pharmaceutical treatments have not been effective enough. The primary objective of this research is to create and enhance cocaine hydrolase (CocH), an engineered enzyme that can convert cocaine into benzoic acid and ecgonine methyl ester, two byproducts that do not have any pharmacological effects, much faster than the body's normal metabolism.

Keywords: Enzyme Therapy, Cocaine Hydrolase (Coch), Cocaine Addiction, Treating Drug Misuse.

INTRODUCTION

To help recovering addicts avoid relapse, the researchers are primarily focused on developing a gene-transfer delivery method that can safely produce large amounts of an effective hydrolase. This enzyme blocks or at least significantly reduces the

effects of cocaine on the brain's reward regions. In the proper metabolism of cocaine, butyrylcholinesterase (BChE) is an important enzyme. An Fc-fused hCocH dimer (hCocH-Fc) was conceived and found as part of the development of the long-acting hCocHs. It is an analog of the catalytic antibody. The biological half-life of the hCocH-Fc is much longer, and it also has a high catalytic effectiveness against cocaine. Twenty days after administration, a single dosage of hCocH-Fc continued to speed up cocaine metabolism in rats, effectively blocking cocaine-induced hyperactivity. The hCocH-Fc might enable dosage every two to four weeks, or even longer, for the treatment of cocaine addiction in humans, taking into account the common finding that the biological half-life of a protein medication in humans is much longer than in rats (Wei et al., 2020).

Maintaining a blood cocaine level below the least effective concentration is the primary goal of pharmacokinetic agents used to treat cocaine addiction (21). The ideal enzyme for treating cocaine addiction would have a lengthy half-life in living organisms and a high catalytic effectiveness against the drug. Hydrolysis of cocaine yields physiologically inert byproducts, and the primary metabolic enzyme that catalyzes this process is BChE. Regrettably, for improved cocaine metabolism, the wild-type BChE catalytic efficiency (kcat/KM) against naturally occurring (-)-cocaine is insufficiently low (kcat = 4.1 min−1 and KM = 4.5 μM) (22). The primary emphasis of the research detailed in this report was on this strategy for the advancement of potential CocHs for the treatment of cocaine addiction. An IL-2 signal peptide followed by Fc(M3)—the A1V/D142E/L144M mutant (33) of Fc—was fused with the N-terminus of CocH3, which was our newly identified cocH3 protein. To further reduce the likelihood of steric interference between Fc(M3) and CocH3, the tetramerization region (amino acid residues from #530 to #574) of CocH3 was subsequently removed. Candidates for the linker (L) were chosen and placed between the Fc(M3) and CocH3 domains. In order to improve the PK profile, several Fc(M3)-L-CocH3 entities were prepared and tested for catalytic activity against cocaine and pharmacokinetic profiles in rats. The results showed that the Fc(M3) fusion on the N-terminus of CocH3 was the most promising (Deng et al., 2022).

BACKGROUND OF THE STUDY

Cocaine misuse causes serious problems on many levels, including the individual, the family, and society as a whole. The euphoric effects and strong addiction potential of cocaine are due to its capacity to prevent dopamine reuptake in the brain. Effective therapy is crucial since prolonged usage may cause neurobiological abnormalities, cardiovascular problems, and social dysfunction. Regardless, there are currently no pharmaceutical therapies for cocaine dependency that have been authorized by the FDA. There is a critical need for new and focused treatment methods since behavioral treatments, while helpful, can have mixed results. One potential solution to the problem of cocaine misuse is cocaine hydrolase (CocH), an engineered enzyme that comes from butyrylcholinesterase (BChE) in humans. Although BChE breaks down cocaine into inert byproducts, the enzyme's sluggish

metabolism makes it unable to delay the onset of effects. The generation of CocH variants with higher catalytic efficiency has been made possible by advances in protein engineering. This allows for quicker breakdown of cocaine. As a means of preventing and treating cocaine overdose and addiction, CocH works by removing the drug from the bloodstream before it may have its euphoric effects. The purpose of this research is to fill important knowledge gaps on CocH by investigating its biochemical characteristics, improving its performance by means of protein engineering, and testing its therapeutic efficacy in animal models. This research intends to provide light on enzyme-based treatments for cocaine consumption and help create a new, effective therapy for this widespread problem by studying the safety, effectiveness, and delivery mechanisms of CocH (Zhang et al., 2020).

PURPOSE OF THE RESEARCH

The fundamental goal of this research is to create and perfect cocaine hydrolase (CocH) as a novel treatment for cocaine addiction and misuse. To lessen the drug's harmful and intoxicating effects, cocaine hydrolase is developed to convert cocaine into inactive metabolites quickly. The goal of this work is to develop an enzyme that can greatly speed up the clearance of cocaine from the circulation by improving the catalytic efficiency of CocH using sophisticated protein engineering. Evaluating the therapeutic potential of CocH in decreasing the behavioral and physiological consequences generated by cocaine is another important goal. The researcher will use preclinical models to see whether it may lessen cocaine's rewarding effects, which will show that it might be a good therapeutic choice. To make sure that CocH is safe to employ in the clinic, the research looks at its immunogenicity, stability, and any off-target effects. In order to obtain long-term and successful therapeutic results, the research also investigates several ways of delivering CocH, such as gene therapy-based methods or direct protein injection. This study's overarching goal is to alleviate the suffering of those afflicted with drug misuse and acute cocaine toxicity by developing a new enzyme-based therapy that overcomes the present shortcomings of pharmaceutical interventions for cocaine addiction. By doing so, the research hopes to speed up the process of creating a therapy that is both effective and safe for patients, which will help lessen the impact of cocaine addiction on society and public health.

LITERATURE REVIEW

Substance abuse, especially cocaine addiction, affects not just the addict but also their loved ones and the larger community. Behavioral treatments, such cognitive-behavioral therapy (CBT) and contingency management, have long been part of the standard toolbox for dealing with cocaine addiction. Unfortunately, the significant recurrence rates associated with these treatments mean that they don't always work, which is why supplementary pharmaceutical interventions are necessary. There is a serious lack of treatment options for cocaine addiction, as no FDA-

approved drugs exist for the condition. This is despite decades of study into the subject. An approach that shows promise is enzyme-based therapy, which uses the body's own metabolic processes to counteract medication. While it is true that human butyrylcholinesterase (BChE) may convert cocaine into inert forms, the enzyme's intrinsically poor catalytic efficiency renders it therapeutically useless. Cocaine hydrolase (CocH) is an improved version of BChE that has much stronger action against cocaine, made possible by recent developments in protein engineering. Research shows that COCH can break down cocaine quickly, which means less of it in the blood and less of its hallucinogenic effects. Animal models of cocaine overdose and cocaine-induced behaviors have shown encouraging outcomes from preclinical investigations on CocH. Additionally, these studies provide evidence that COCH may mitigate the rewarding effects of cocaine, which may lead to a decrease in cravings and an elimination of the need to relapse. A number of obstacles must yet be overcome before the enzyme can be considered stable in vivo, its immunogenicity can be reduced, and effective delivery mechanisms may be developed to provide long-term therapeutic benefits. One promising gene therapy option is the adeno-associated virus (AAV)-mediated delivery of coenzyme H (CocH), which might provide a new way to treat patients over the long term by expressing the enzyme. Addressing safety problems is also emphasized in the literature (Shimomura et al., 2019).

RESEARCH QUESTIONS

What is the impact of Coping mechanisms on Therapeutical Treatment of Cocaine Abuse Treatment?

METHODS

Quantitative research refers to studies that examine numerical readings of variables using one or more statistical models. The social environment may be better understood via quantitative research. Quantitative approaches are often used by academics to study problems that impact individuals. Objective data presented in a graphical format is a byproduct of quantitative research. Numbers are crucial to quantitative research and must be collected and analyzed in a systematic way. Averages, predictions, correlations, and extrapolating findings to larger groups are all possible with their help.

RESEARCH DESIGN

Quantitative data analysis was conducted using SPSS version 25. The combination of the odds ratio and the 95% confidence interval provided information about the

nature and trajectory of this statistical association. The p-value was set at less than 0.05 as the statistical significance level. The data was analyzed descriptively to provide a comprehensive understanding of its core characteristics. Quantitative approaches are characterized by their dependence on computing tools for data processing and their use of mathematical, arithmetic, or statistical analyses to objectively assess replies to surveys, polls, or questionnaires.

SAMPLING

After pilot research with 20 Chinese Researcher, 1100 Rao-soft pupils were included in the final Investors. Male and female Researcher were picked at random and then given a total of 1,455 surveys to fill out. A total of 1253 questionnaires were used for the calculation after 1300 were received and 47 were rejected due to incompleteness.

DATA AND MEASUREMENT

A questionnaire survey served as the main data collector for the study. There were two sections to the survey: (A) General demographic information and (B) Online & non-online channel factor replies on a 5-point Likert scale. Secondary data was gathered from a variety of sources, with an emphasis on online databases.

STATISTICAL TOOLS

Descriptive anaAlysis was used to grasp the fundamental character of the data. The researcher applied ANOVA for the analysis of the data

CONCEPTUAL FRAMEWORK



RESULTS

FACTOR ANALYSIS

One typical use of Factor Analysis (FA) is to verify the existence of latent components in observable data. When there are not easily observable visual or diagnostic markers, it is common practice to utilize regression coefficients to produce ratings. In FA, models are essential for success. Finding mistakes, intrusions, and obvious connections are the aims of modelling. One way to assess datasets produced by multiple regression studies is with the use of the Kaiser-Meyer-Olkin (KMO) Test. They verify that the model and sample variables are representative. According to the numbers, there is data duplication. When the proportions are less, the data is easier to understand. For KMO, the output is a number between zero and one. If the KMO value is between 0.8 and 1, then the sample size should be enough. These are the permissible boundaries, according to Kaiser: The following are the acceptance criteria set by Kaiser:

A dismal 0.050 to 0.059, subpar 0.60 to 0.69

Middle grades often range from 0.70 to 0.79.

Exhibiting a quality point score between 0.80 and 0.89.

They are astonished by the range of 0.90 to 1.00.

Table 1: KMO and Bartlett's Test for Sampling Adequacy Kaiser-Meyer-Olkin measurement: .895

KMO and Bartlett's Test		
Kaiser-Meyer-Olkin Measure of Sampling Adequacy.		.895
Bartlett's Test of Sphericity	Approx. Chi-Square	3252.968
	df	190
	Sig.	.000

The outcomes of Bartlett's test of sphericity are as follows: Approximately chi-square degrees of freedom = 190 significance = 0.000

The overall importance of the correlation matrices was also validated by Bartlett's Test of Sphericity. The Kaiser-Meyer-Olkin sampling adequacy is 0.895. Utilizing Bartlett's sphericity test, researchers obtained a p-value of 0.00. A notable result from Bartlett's sphericity test indicated that the correlation matrix is not valid.

INDEPENDENT VARIABLE

The Development of Cocaine Hydrolase: The fast breakdown of cocaine into inert byproducts like benzoic acid and ecgonine methyl ester may be catalyzed by a genetically engineered enzyme called cocaine hydrolase (CocH). The catalytic efficiency and specificity of CocH, which is derived from or based on human butyrylcholinesterase (BChE), are greatly improved by modifications. By increasing the rate at which cocaine is metabolized in the blood, CocH aims to lessen the drug's harmful and intoxicating effects. This makes it a potentially useful medicinal substance in the fight against cocaine addiction, overdose, and its aftereffects. Supporting both short-term treatments and long-term addiction management techniques, CocH reduces the euphoric and reinforcing effects of cocaine by blocking its pathways in the brain (Zheng et al., 2019).

FACTOR

Coping Mechanism: A person's coping mechanisms are the ways in which they deal with stressful emotions, challenging events, and stress in general. To be mentally healthy and deal with life's difficulties, these techniques are essential. People use coping methods to lessen the impact of negative emotions, adjust to new circumstances, and ultimately overcome adversity. There is a wide variety of coping skills, from mental tactics to physical pursuits. There are two main categories into which these systems fall: adaptive and maladaptive. People may learn to manage stress in a positive way by developing adaptive coping strategies. Things like talking to friends and family, learning relaxation methods, getting some exercise, and solving problems are all great examples. Better results when stress is present are the result of these tactics' promotion of resilience and emotional control (Deng et al., 2022).

DEPENDENT VARIABLE

Therapeutical Treatment of Cocaine Abuse Treatment: Medical and psychological interventions that aim to cure, manage, or relieve symptoms of a certain health condition or illness are collectively known as therapeutical treatments. The goal of these individualized therapies is to alleviate symptoms, get patients back to normal functioning, and boost their health. Medications are one kind of pharmacological therapy; physical therapies include rehabilitation and exercises; counseling and cognitive-behavioral therapy are two examples of psychological therapies; and complementary therapies include acupuncture and massage. In addition to relieving

symptoms, therapeutic therapy aims to improve the patient's health in the long run, stop the disease from coming back, and make their lives better in general. It is common practice to tailor therapeutic interventions to each patient by learning about their unique symptoms, medical background, and the extent of their illness. It may help with the management of long-term health issues, the treatment of acute diseases, and the rehabilitation following injuries or surgeries (Zheng et al., 2020).

Relationship between Coping Mechanisms and Therapeutical Treatment of Cocaine Abuse Treatment: In the context of managing and overcoming difficulties to one's physical or mental health, coping strategies and therapeutic therapy are intimately related. To alleviate symptoms or cure health disorders, therapeutic therapy entails systematic, professional interventions, in contrast to coping mechanisms, which are individual ways for dealing with stress and tough emotions. Both are vital to a holistic strategy for emotional and physical well-being, and they aid in recovery in different ways. When people experience emotional or mental distress, coping methods are often their first defensive mechanism. These skills may be honed and improved with practice, allowing people to better control their behaviors in stressful circumstances. In order to alleviate their anxiety, a person may use adaptive coping methods such as practicing relaxation techniques or reaching out to others for support (Michely et al., 2020). When people are able to effectively handle the emotional and psychological difficulties, including dissatisfaction or fear of recovery, that may develop as a result of therapeutic therapy, the treatments become more successful. To the contrary, when unhealthy or maladaptive coping processes (such drug abuse or avoidance) are impeding recovery, therapeutic therapy may help people establish more adaptive coping methods. For instance, cognitive-behavioral therapy (CBT) is a kind of treatment that aims to assist patients in identifying and altering unhealthy ways of dealing with stress, anxiety, and depression. Medications and psychotherapies are two examples of therapeutic treatments that may help people enhance their coping abilities. Medications for mental health issues, such as anxiety or depression, may alleviate symptoms, allowing people to more readily use adaptive coping techniques. Supporting long-term rehabilitation and emotional control, patients often build more robust coping mechanisms as treatment advances. To summarize, there is a connection between therapeutic therapy and coping methods. Individuals may learn to cope with the stresses of everyday life and the emotional challenges they face, and they can get the professional assistance they need to get to the bottom of their health problems and make real, long-term changes via therapeutic therapy. When combined, they provide a comprehensive strategy for dealing with immediate and future health issues (Glass et al., 2020).

Based on the above discussion, the researcher formulated the following hypothesis, which was to analyse the relationship between Coping Mechanisms and Therapeutical Treatment of Cocaine Abuse Treatment .

H01: “There is no significant relationship between Coping Mechanisms and Therapeutical Treatment of Cocaine Abuse Treatment”

H1: “There is a significant relationship between Coping Mechanisms and Therapeutical Treatment of Cocaine Abuse Treatment”

Table 2: H_1 ANOVA Test

ANOVA					
Sum					
	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	39588.620	523	4978.486	619.312	.000
Within Groups	492.770	729	2.597		
Total	40081.390	1252			

This investigation yields remarkable results. The F value is 619.312, achieving significance with a p-value of .000, which is below the .05 alpha threshold. This means “H1: There is a significant relationship between Coping Mechanisms and Therapeutical Treatment of Cocaine Abuse Treatment” The alternative hypothesis is accepted, whereas the null hypothesis is rejected.

CONCLUSION

A significant advancement in the therapeutic treatment of cocaine usage and addiction has been made with the creation of cocaine hydrolase (CocH). The capacity to quickly convert cocaine into inactive metabolites has been shown by CocH via optimization and genetic engineering, minimizing the danger of toxicity and diminishing the drug's psychoactive effects. Treating the shortcomings of current methods, this novel enzyme-based therapy may be useful in conjunction with behavioral therapies and more conventional pharmaceutical procedures. In animal models, preclinical research has shown that CocH can successfully decrease cocaine-induced behaviors and avoid overdose, suggesting that it may be useful as a therapeutic and preventative measure. Research into other ways of delivery, such as gene therapy and recombinant protein injection, highlights how versatile CocH is in producing long-lasting therapeutic benefits. While there are still some obstacles to overcome, such as improving enzyme stability, reducing immunogenicity, and guaranteeing safety in clinical settings, the progress made thus far is encouraging. The findings of this research have important implications for the future of enzyme-based treatments, both for the treatment of cocaine addiction and for the prevention of drug overdoses more generally. With more study and clinical trials, COCH has the potential to completely change the way cocaine is treated, providing a fresh and efficient answer to a widespread public health issue. In the end, this study opens the door to a more holistic strategy for treating addiction, one that

merges modern biotechnology with time-tested therapy methods, ultimately leading to better results for those struggling with cocaine dependency.

REFERENCES

1. Wei H, Zhang T, Zhan CG, Zheng F. Cebranopadol reduces cocaine self-administration in male rats: dose, treatment and safety considerations. Neuropharmacology. 2020;172:108128.
2. Deng J, Zhang T, Shang L, Zhan CG, Zheng F. Recovery of dopaminergic system after cocaine exposure and impact of a long-acting cocaine hydrolase. Addict Biol. 2022;27(4):e13179.
3. Zhang T, Wei H, Deng J, Zheng F, Zhan CG. Clinical potential of a rationally engineered enzyme for treatment of cocaine dependence: long-lasting blocking of the psychostimulant, discriminative stimulus, and reinforcing effects of cocaine. Neuropharmacology. 2020;176:108251.
4. Shimomura ET, Jackson GF, Paul BD. Cocaine, crack cocaine, and ethanol: a deadly mix. In: Dasgupta A, editor. Critical Issues in Alcohol and Drugs of Abuse Testing. 2nd ed. Elsevier; 2019. p. 215–24.
5. Zheng X, Shang L, Zhan CG, Zheng F. In vivo characterization of toxicity of norcocaethylene and norcocaine identified as the most toxic cocaine metabolites in male mice. Drug Alcohol Depend. 2019;204:107462.
6. Deng J, Zheng X, Shang L, Zhan CG, Zheng F. Gender differences in cocaine-induced hyperactivity and dopamine transporter trafficking to the plasma membrane. Addict Biol. 2022;27(2):e13236.
7. Zheng F, Chen X, Kim K, Zhang T, Huang H, Zhou S, et al. Structure-based design and discovery of a long-acting cocaine hydrolase mutant with improved binding affinity to neonatal Fc receptor for treatment of cocaine abuse. AAPS J. 2020;22(3):62.
8. Glass JE, Nunes EV, Bradley KA. Contingency management: a highly effective treatment for substance use disorders and the legal barriers that stand in its way. Health Aff (Millwood). 2020 Mar 11.
9. Hedegaard H, Minino AM, Warner M. Drug overdose deaths in the United States, 1999-2018. NCHS Data Brief. 2020;(356):1–8.
10. Michely J, Viswanathan S, Hauser TU, Delker L, Dolan RJ, Grefkes C. The role of dopamine in dynamic effort-reward integration. Neuropsychopharmacology. 2020;45:1448–53.